MVCD1
MCID: MCR129
MIFTS: 67

Microvascular Complications of Diabetes 1 (MVCD1)

Categories: Cardiovascular diseases, Eye diseases, Genetic diseases, Nephrological diseases, Neuronal diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Microvascular Complications of Diabetes 1

MalaCards integrated aliases for Microvascular Complications of Diabetes 1:

Name: Microvascular Complications of Diabetes 1 57 73 12 38
Proliferative Diabetic Retinopathy 11 73 53 14 16 71 33
Microvascular Complications of Diabetes, Susceptibility to, 1 57 28 5
Non-Proliferative Diabetic Retinopathy 73 16
Nonproliferative Diabetic Retinopathy 71 33
Diabetic Nephropathy 73 71
Mvcd1 57 73
Diabetes Mellitus, Independent of Type with Proliferative Retinopathy 33
Nonproliferative Retinopathy, Diabetic, Susceptibility to 57
Proliferative Retinopathy, Diabetic, Susceptibility to 57
Nonproliferative Retinopathy, Diabetic 57
Proliferative Retinopathy, Diabetic 57
Complications of Diabetes Mellitus 71
Diabetic End-Stage Renal Disease 73
Diabetic Neuropathies 71
Diabetic Neuropathy 73
Pdr 11

Classifications:



External Ids:

Disease Ontology 11 DOID:13207
OMIM® 57 603933
OMIM Phenotypic Series 57 PS603933
ICD9CM 34 362.02
MeSH 43 D048909
NCIt 49 C84457
SNOMED-CT 68 154679002
UMLS 71 C0004606 C0011881 C0011882 more

Summaries for Microvascular Complications of Diabetes 1

UniProtKB/Swiss-Prot: 73 Pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis.

MalaCards based summary: Microvascular Complications of Diabetes 1, also known as proliferative diabetic retinopathy, is related to background diabetic retinopathy and severe nonproliferative diabetic retinopathy, and has symptoms including sciatica and neuralgia. An important gene associated with Microvascular Complications of Diabetes 1 is VEGFA (Vascular Endothelial Growth Factor A), and among its related pathways/superpathways are Innate Immune System and Apoptotic Pathways in Synovial Fibroblasts. The drugs Pentoxifylline and Captopril have been mentioned in the context of this disorder. Affiliated tissues include retina, kidney and eye, and related phenotypes are homeostasis/metabolism and nervous system

More information from OMIM: 603933 PS603933

Related Diseases for Microvascular Complications of Diabetes 1

Diseases in the Microvascular Complications of Diabetes 1 family:

Microvascular Complications of Diabetes 2 Microvascular Complications of Diabetes 3
Microvascular Complications of Diabetes 4 Microvascular Complications of Diabetes 5
Microvascular Complications of Diabetes 6 Microvascular Complications of Diabetes 7

Diseases related to Microvascular Complications of Diabetes 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1100)
# Related Disease Score Top Affiliating Genes
1 background diabetic retinopathy 32.8 VEGFA ICAM1 CXCL8 CCL2 ANGPT2
2 severe nonproliferative diabetic retinopathy 32.7 VEGFA ICAM1 CCL2
3 diabetic polyneuropathy 32.5 VEGFA IGF1 FGF2
4 macular holes 31.7 VEGFA TGFB2 SERPINF1 CXCL8 CCL2 ANGPT2
5 renal fibrosis 31.5 TIMP1 TGFB2 MMP9 HGF FGF2 CCN2
6 glomerulonephritis 31.5 VCAM1 ICAM1 CCN2 CCL2
7 type 1 diabetes mellitus 31.5 VEGFA SST IGF1 ICAM1 CXCL8
8 vitreous detachment 31.2 VEGFA TGFB2 GFAP FGF2
9 retinal ischemia 31.2 VEGFA ICAM1 GFAP FGF2 CCL2
10 endophthalmitis 31.2 VEGFA ICAM1 FLT1 CXCL8
11 nephrosclerosis 31.1 VEGFA CCN2 CCL2
12 insulin-like growth factor i 31.0 VEGFA SST IGF1 FGF2
13 uveitis 30.9 VEGFA TGFB2 SERPINF1 ICAM1 CXCL8 CCL2
14 lipid metabolism disorder 30.9 VCAM1 IGF1 ICAM1 CCL2
15 retinal vein occlusion 30.9 VEGFA SERPINF1 CXCL8 CXCL12 CCL2 ANGPT2
16 retinal vascular disease 30.9 VEGFA SERPINF1 ICAM1 FLT1 FGF2 CXCL8
17 proteasome-associated autoinflammatory syndrome 1 30.8 VCAM1 MMP9 ICAM1 CXCL8 CCL2
18 carpal tunnel syndrome 30.8 VEGFA CCN2 CCL2
19 congestive heart failure 30.8 VEGFA MMP9 ANGPT2 ANGPT1
20 preretinal fibrosis 30.8 VEGFA TGFB2 HGF GFAP CCN2 ANGPT2
21 cataract 30.8 VEGFA TIMP1 TGFB2 SERPINF1 IGF1 ICAM1
22 carotid artery disease 30.7 VCAM1 MMP9 ICAM1
23 diabetic angiopathy 30.7 VEGFA VCAM1 ICAM1 CCL2
24 osteoarthritis 30.7 TIMP1 MMP9 IGF1 CXCL8
25 peripheral artery disease 30.7 VEGFA VCAM1 ICAM1 CCL2
26 central retinal vein occlusion 30.6 VEGFA ICAM1 FLT1 CCL2
27 neuritis 30.6 VEGFA MMP9 GFAP CXCL8 CCL2
28 pyelonephritis 30.6 TIMP1 MMP9 CXCL8 CCL2
29 fatty liver disease 30.6 VCAM1 TIMP1 IGF1 CCL2
30 fibromyalgia 30.6 IGF1 CXCL8 CCL2
31 vasculitis 30.6 VCAM1 ICAM1 CXCL8 CCL2
32 leptospirosis 30.6 ICAM1 CXCL8 CCL2
33 carotid stenosis 30.5 VEGFA VCAM1 MMP9 ICAM1 CXCL8
34 encephalitis 30.5 VCAM1 GFAP CXCL8 CCL2
35 arteriosclerosis obliterans 30.5 VCAM1 ICAM1 HGF
36 respiratory failure 30.5 VEGFA ICAM1 CXCL8 CCL2 ANGPT2
37 aortic atherosclerosis 30.4 VCAM1 ICAM1 CCL2
38 apnea, obstructive sleep 30.4 VEGFA IGF1 ICAM1 CXCL8
39 tuberous sclerosis 30.4 VEGFA SST IGF1 GFAP
40 peripheral vascular disease 30.4 VEGFA VCAM1 ICAM1 CCL2
41 severe pre-eclampsia 30.4 VEGFA VCAM1 FLT1
42 cardiovascular system disease 30.4 VCAM1 IGF1 ICAM1 CXCL12 CCL2
43 obstructive nephropathy 30.4 HGF CCN2 CCL2
44 intermittent claudication 30.4 VEGFA IGF1 ANGPT2
45 glucose intolerance 30.4 VCAM1 SST IGF1 CCL2
46 osteonecrosis 30.4 VEGFA MMP9 FGF2
47 keratitis, hereditary 30.4 VEGFA MMP9 FGF2 CXCL8
48 cystitis 30.3 VEGFA CXCL8 CCL2
49 amyotrophic lateral sclerosis 1 30.3 VEGFA MMP9 IGF1 GFAP FGF2 CXCL8
50 pulmonary edema 30.3 ICAM1 HGF CXCL8

Comorbidity relations with Microvascular Complications of Diabetes 1 via Phenotypic Disease Network (PDN): (show all 22)


Acute Cystitis Acute Kidney Failure
Benign Essential Hypertension Chronic Kidney Disease
Decubitus Ulcer Deficiency Anemia
Diabetic Cataract Diabetic Polyneuropathy
Heart Disease Hypertension, Essential
Hypoglycemia Hypoglycemic Coma
Hypothyroidism Intermediate Coronary Syndrome
Iron Deficiency Anemia Kidney Disease
Microvascular Complications of Diabetes 7 Mitral Valve Disease
Neurogenic Arthropathy Peripheral Vascular Disease
Rubeosis Iridis Transient Cerebral Ischemia

Graphical network of the top 20 diseases related to Microvascular Complications of Diabetes 1:



Diseases related to Microvascular Complications of Diabetes 1

Symptoms & Phenotypes for Microvascular Complications of Diabetes 1

Clinical features from OMIM®:

603933 (Updated 08-Dec-2022)

UMLS symptoms related to Microvascular Complications of Diabetes 1:


sciatica; neuralgia

GenomeRNAi Phenotypes related to Microvascular Complications of Diabetes 1 according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.18 ANGPT1 ANGPT2 CCL2 CCN2 CXCL12 CXCL8
2 no effect GR00402-S-2 10.18 ANGPT2 CCL2 CCN2 CXCL12 FGF2 FLT1

MGI Mouse Phenotypes related to Microvascular Complications of Diabetes 1:

45 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.4 ANGPT1 ANGPT2 CCL2 CCN2 FGF2 FLT1
2 nervous system MP:0003631 10.37 ANGPT1 CCL2 CXCL12 FGF2 FLT1 GFAP
3 cardiovascular system MP:0005385 10.33 ANGPT1 ANGPT2 CCL2 CCN2 CXCL12 FGF2
4 growth/size/body region MP:0005378 10.32 ANGPT1 CCL2 CCN2 FLT1 GFAP HGF
5 cellular MP:0005384 10.28 ANGPT2 CCL2 CCN2 CXCL12 FGF2 FLT1
6 muscle MP:0005369 10.25 ANGPT1 CCL2 CXCL12 FGF2 FLT1 GFAP
7 immune system MP:0005387 10.24 ANGPT1 ANGPT2 CCL2 CXCL12 FLT1 GFAP
8 digestive/alimentary MP:0005381 10.16 ANGPT2 CCL2 CCN2 GFAP ICAM1 MMP9
9 reproductive system MP:0005389 10.1 ANGPT2 CCL2 CXCL12 FGF2 FLT1 IGF1
10 neoplasm MP:0002006 10.08 CCL2 FGF2 ICAM1 IGF1 MMP9 TIMP1
11 skeleton MP:0005390 10 CCL2 CCN2 FGF2 HGF IGF1 MMP9
12 vision/eye MP:0005391 9.97 ANGPT1 ANGPT2 CCL2 CCN2 FGF2 FLT1
13 hematopoietic system MP:0005397 9.8 ANGPT2 CCL2 CXCL12 FGF2 FLT1 HGF
14 mortality/aging MP:0010768 9.58 ANGPT1 ANGPT2 CCL2 CCN2 CXCL12 FGF2

Drugs & Therapeutics for Microvascular Complications of Diabetes 1

Drugs for Microvascular Complications of Diabetes 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 472)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
2
Captopril Approved Phase 4 62571-86-2 44093
3
Clopidogrel Approved Phase 4 120202-66-6, 113665-84-2 60606
4
Moxonidine Approved, Investigational Phase 4 75438-57-2 4810
5
Levoleucovorin Approved, Experimental, Investigational Phase 4 68538-85-2, 58-05-9, 73951-54-9 149436 6006
6
Hydroxocobalamin Approved Phase 4 13422-51-0 15589840 44475014
7
Dipivefrin Approved Phase 4 52365-63-6 3105
8
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
9
Alprostadil Approved, Investigational Phase 4 745-65-3 5280723
10
Amlodipine Approved Phase 4 88150-42-9 2162
11
Atenolol Approved Phase 4 29122-68-7 2249
12
Doxazosin Approved Phase 4 74191-85-8 3157
13
Acetylsalicylic acid Approved, Vet_approved Phase 4 50-78-2 2244
14
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
15
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
16
Simvastatin Approved Phase 4 79902-63-9 54454
17
Clonidine Approved Phase 4 4205-91-8, 4205-90-7 2803 20179
18
Insulin glulisine Approved Phase 4 207748-29-6
19
Insulin glargine Approved Phase 4 160337-95-1 118984454
20
Lixisenatide Approved Phase 4 320367-13-3 90472060 16139342
21
Glucagon Approved Phase 4 16941-32-5 16133228 16186314
22
Zaleplon Approved, Illicit, Investigational Phase 4 151319-34-5 5719
23
Tacrolimus Approved, Investigational Phase 4 104987-11-3 6473866 445643
24
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
25
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
26
Carbamide peroxide Approved Phase 4 124-43-6
27
Candesartan cilexetil Approved Phase 4 145040-37-5
28
Allopurinol Approved Phase 4 315-30-0 2094 135401907
29
Nisoldipine Approved Phase 4 63675-72-9 4499
30
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
31
Probucol Approved, Investigational Phase 4 23288-49-5 4912
32
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
33
Exenatide Approved, Investigational Phase 4 141758-74-9 45588096
34
Atorvastatin Approved Phase 4 134523-00-5 60823
35
Indapamide Approved Phase 4 26807-65-8 3702
36
Dapagliflozin Approved Phase 4 461432-26-8 9887712
37
Sodium citrate Approved, Investigational Phase 4 68-04-2 23431961
38
Verapamil Approved Phase 4 152-11-4, 52-53-9 2520
39
Trandolapril Approved Phase 4 87679-37-6 5484727
40
Saxagliptin Approved Phase 4 361442-04-8 11243969
41
Nabilone Approved, Investigational Phase 4 51022-71-0 39860 5284592
42
Capsaicin Approved Phase 4 404-86-4 1548943
43
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
44
Acetaminophen Approved Phase 4 103-90-2 1983
45
Histamine Approved, Investigational Phase 4 51-45-6 774
46
Bromocriptine Approved, Investigational, Withdrawn Phase 4 25614-03-3 31101
47
Amitriptyline Approved Phase 4 50-48-6 2160
48
Quinapril Approved, Investigational Phase 4 82586-55-8, 85441-61-8 54892
49
Cetirizine Approved Phase 4 83881-51-0 2678
50
Sildenafil Approved, Investigational Phase 4 139755-83-2, 171599-83-0 5212 135398744

Interventional clinical trials:

(show top 50) (show all 968)
# Name Status NCT ID Phase Drugs
1 Effect of Folic Acid, Vitamin B6 and Vitamin B12 in Diabetic Retinopathy Unknown status NCT01921192 Phase 4 Folic Acid, vit B6 and B12;Placebo
2 Pattern Scan Laser System vs Regular Photocoagulation System: Changes in Macular Edema Post Treatment. Unknown status NCT00563628 Phase 4
3 Pattern Scan Laser System vs Regular Photocoagulation System: Changes in Electroretinograms and Contrast Sensitivity Post Treatment. Unknown status NCT00563043 Phase 4
4 Three Arm, Prospective, Single-blind, Randomized Study Comparing Ranibizumab Plus Green Diode Laser Versus Ranibizumab Plus Pattern Scan Laser (Pascal) Versus Ranibizumab (Monotherapy) for Proliferative Diabetic Retinopathy. Unknown status NCT02005432 Phase 4 Intravitreal Ranibizumabe;panfotocoagulation (PASCAL);panfotocoagulation (PRP) single shoot (ETDRS)
5 Prospective, Single-blind, Randomised, Controlled, Multi-centre Study to Evaluate the Benefit of Ranibizumab as an Adjunctive Therapy to Vitrectomy for Patients With Proliferative Diabetic Retinopathy Combined With Diabetic Macular Oedema Unknown status NCT04464694 Phase 4 Ranibizumab
6 A Pilot Study to Determine if Intravitreal Injections of Pegaptanib Sodium (Macugen) Given Every 12 Weeks for a Year After an Induction Phase of Three Injections Every 6 Weeks Will Reduce the Progression of Proliferative Diabetic Retinopathy in Patients Without Significant Vitreous Hemorrhage in Comparison to Treatment With Retinal Photocoagulation Alone and After an Induction Phase Unknown status NCT01486771 Phase 4 Macugen ® (pegaptanib sodium)
7 Different Day Regimes of Preoperative CONbercept Administration on CytokinEs of Proliferative Diabetic Retinopathy Patients Undergoing Vitrectomy: a Prospective Randomized Controlled Clinical Trial (CONCEPT) Unknown status NCT03506750 Phase 4 IVC
8 Efficacy of Calcium Dobesilate in Treating Chinese Patients With Mild to Moderate Non-proliferative Diabetic Retinopathy (CALM-DR): a Single-blind, Multicenter, Cluster-randomized, Controlled Trial Unknown status NCT04283162 Phase 4 Calcium Dobesilate
9 Panretinal Photocoagulation for Proliferative Diabetic Retinopathy in a Single Session Using Low Fluence Parameters Unknown status NCT01023698 Phase 4
10 Pilot Study Investigating the Use of Intravitreal Ranibizumab in the Treatment of Vitreous Hemorrhage in Proliferative Diabetic Retinopathy Unknown status NCT01824043 Phase 4 intravitreal ranibizumab injections
11 Effects of SGLT2 Inhibition Treatment on Different Levels of Albuminuria in Patients With Type 2 Diabetes: a Prospective Interventional Study Unknown status NCT04127084 Phase 4 SGLT2 Inhibition
12 Effect of Aldosterone Antagonism in the Reduction of Albuminuria and Diastolic Disfunction of Patients With Diabetic Nephropathy. Unknown status NCT00870402 Phase 4 Spironolactone;Placebo
13 Clinical Trial Technology Development for the Validation of Surrogate Prognostic Markers in Patients With Diabetic Nephropathy Unknown status NCT01673204 Phase 4 Calcitriol;Placebo
14 Phase 4 Study of Mechanisms of Low Protein Diet Supplemented With Ketoanalogs on Reducing Proteinuria and Maintaining Nutritional Status in Type 2 Diabetic Nephropathy Unknown status NCT01300273 Phase 4
15 A Prospective, Randomized, Two Period, With an Intermediate Wash Out Period, Cross-over Study to Compare the Effects of Either Combined Therapy With Ramipril and Clopidogrel or Ramipril Monotherapy on Oxidative Stress, Vascular Inflammation and Endothelial Dysfunction in Patients With Type 2 Diabetes and Diabetic Nephropathy Unknown status NCT01743014 Phase 4 Ramipril;Clopidogrel
16 Effect of Intravenous and Oral Therapy With Sulodexide on Albuminuria in Type 2 Diabetic Patients Unknown status NCT01316068 Phase 4 intravenous use of sulodexide followed by oral use;use of sulodexide orally only
17 Prevention of Renal Complications of Diabetes With Thiamine Unknown status NCT01725412 Phase 4
18 Comparative Effecacy of Metformin and Vildagliptin on Cardiometabolic Risk Factors, Metabolic Syndrome, and Diabetic Nephropathy Progression Unknown status NCT04485845 Phase 4 Vildagliptin;Captopril Tablets;MetFORMIN 500 Mg Oral Tablet
19 Pentoxifylline Effect on Renal Function, Oxidative Stress, Inflammation, and Fibrosis Markers, and Quality of Life in Patients With Diabetic Nephropathy Unknown status NCT03664414 Phase 4 pentoxifylline
20 Sympathetic Nervous System Inhibition for the Treatment of Diabetic Nephropathy Unknown status NCT01094769 Phase 4 Moxonidine;Placebo
21 Bi-Axial Rotating Magnetic Field Therapy in Refractory Neuropathic Foot Pain Secondary to Diabetic Peripheral Neuropathy. Multi-Center, Randomized Placebo Controlled Trial Unknown status NCT00123136 Phase 4
22 Inspiratory Muscle Training in Patients With Autonomic Neuropathic: a Randomized Trial Unknown status NCT00752440 Phase 4
23 Evaluation of the Impact of Subject and Staff Training on the Pregabalin vs. Placebo Difference in Subjects With Painful Diabetic Neuropathy (PDN) Unknown status NCT01770964 Phase 4 Pregabalin;placebo
24 The Effect of Bevacizumab on Peripheral Retinal Changes as Imaged by Wide -Field Fluorescein Angiography in Diabetic Macular Edema Completed NCT02096874 Phase 4 Bevacizumab
25 Prospective Randomized Controlled Study of Intravitreal Injection of 0.16 mg Bevacizumab One Day Before Surgery for Proliferative Diabetic Retinopathy Completed NCT01854593 Phase 4 Bevacizumab
26 Morphological and Functional Retinal Changes Following Retinal Photocoagulation Using a Semiautomated Patterned Scanning Laser System in Proliferative Retinopathy or Macular Edema Secondary to Diabetes Mellitus or Retinal Vein Occlusion Completed NCT00682240 Phase 4
27 Pain Using Reduced Fluence Parameters in Photocoagulation for Diabetic Retinopathy. Completed NCT00802269 Phase 4
28 Intravitreal Bevacizumab for Surgical Treatment of Severe Proliferative Diabetic Retinopathy Completed NCT01025934 Phase 4 Bevacizumab
29 Different Conbercept Injection Methods in Treatment of Severe Proliferative Diabetic Retinopathy Completed NCT02816710 Phase 4 Conbercept
30 Intravitreal Bevacizumab for Proliferative Diabetic Retinopathy With New Dense Vitreous Hemorrhage After Full Panretinal Photocoagulation Completed NCT01724385 Phase 4 intravitreal injection of bevacizumab
31 Effect of Continuous Positive Airway Pressure on the Progression of Vascular Retinal Disease in Patients With Sleep Apnea and Non-proliferative Diabetic Retinopathy. A Randomized Clinical Trial Completed NCT02874313 Phase 4 Pharmacological treatment
32 Prospective, Single-center, Six-month Study of Intravitreal Ranibizumab for Macular Edema With Nonproliferative Diabetic Retinopathy: Effects on Microaneurysm Turnover and Non-perfused Retinal Area Completed NCT02834663 Phase 4 Lucentis
33 A Multicenter, Randomized, Double-blind Non-inferiority Trial to Evaluate the Efficacy and Safety of Entelon® as Compared to Doxium Tab. And Placebo for the Treatment of Nonproliferative Diabetic Retinopathy Completed NCT03962296 Phase 4 Vitis vinifera extract;Calcium Dobesilate;Placebo
34 A Randomised, Double-blind, Placebo-controlled, Multicenter Trial to Investigate the Preventive Effect of BIBR277 (Telmisartan) in Diabetic Nephropathy on Transition From Incipient to Overt Nephropathy - Incipient to Overt : Angiotensin 2 Receptor Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION Study - Completed NCT00153088 Phase 4 Telmisartan capsule 40 mg;Placebo;Telmisartan capsule 80 mg
35 Lipo-prostaglandin E1 Improves Renal Hypoxia Evaluated by BOLD-MRI in Patients Completed NCT02628106 Phase 4 Lipo-PGE1
36 Nephropathy in Type 2 Diabetes: Effects of an Intensive Multifactorial Intervention Trial on Cardio-renal Events. Completed NCT00535925 Phase 4 SoC therapy;irbesartan;ramipril;hydrochlorothiazide;furosemide;amlodipine;atenolol;doxazosin;clonidine;insulin;simvastatin;fibrate;erythropoietin;aspirin
37 Combined Diabetes-Renal Multifactorial Intervention In Patients With Advanced Diabetic Nephropathy (ADN) Completed NCT00708981 Phase 4
38 A Phase 4, Mono-center, Randomized, Open Label, Comparator-controlled, Parallel-group, Mechanistic Intervention Trial to Assess the Effect of 8-week Treatment With the Glucagon-like Peptide-1 Receptor Agonist Lixisenatide Versus Insulin Glulisine on Renal Physiology and Biomarkers in Insulin Glargine-treated Patients With Type 2 Diabetes Mellitus Completed NCT02276196 Phase 4 Lixisenatide;Insulin glulisine
39 Effect of Enalapril and Losartan Association Therapy on Proteinuria and Inflammatory Biomarkers in Diabetic Nephropathy: a Clinical Trial on Type 2 Diabetes Mellitus Completed NCT00419835 Phase 4 enalapril;losartan
40 FGF-23 and Endothelial Dysfunction in Diabetic Proteinuric Patients Completed NCT01703234 Phase 4 Ramipril
41 Effect of Sarpogrelate On the Nephropathy in Type 2 Diabetes Completed NCT01869881 Phase 4 Anplag(Sarpogrelate);Placebo
42 Effect of Renin Angiotensin System Blockade on CD95 and ADMA Levels in Type-2 Diabetic Patients With Proteinuria Completed NCT00893425 Phase 4 ramipril
43 A 28-week, Randomised, Open-label, Parallel-Group, Multi-Center Study To Find the Effective Dose of Candesartan Cilexetil (Atacand) for Renoprotection in Korean Hypertensive Patients With Non-diabetic Nephropathy Completed NCT00573430 Phase 4 Candesartan Cilexetil;Candesartan Cilexetil 32mg
44 Antiproteinuric Effect of Valsartan, Lisinopril and Valsartan Plus Lisinopril in Non-diabetic and Diabetic Renal Disease: a Randomized, Double Blind, Parallel Group, Controlled Trial With 5 Months Follow-up Completed NCT00171574 Phase 4 Valsartan;Valsartan plus HCTZ;Lisinopril
45 A Prospective, Multi-center, Randomized, Open-label, Parallel-arm Controlled Study of Treating Type 2 Diabetic Nephropathy (Stage II-IV) With Alfacalcidol and Irbesartan Completed NCT03147677 Phase 4 Alfacalcidol;Irbesartan
46 Effect of Urinary Alkalinization on Urine Uric Acid Precipitation and Crystallization in Adults With Type 1 DiabetesL a Open-label Trial Completed NCT02502071 Phase 4 sodium bicarbonate
47 A Double-Blind Clinical Trial of Benfotiamine Treatment in Diabetic Nephropathy Completed NCT00565318 Phase 4 Benfotiamine;Placebo
48 A Double-blind, Randomized, Placebo Controlled Trial of Allopurinol in Patients With Type 1 Diabetes and Microalbuminuria Completed NCT02829177 Phase 4 Allopurinol;Placebo
49 A Multicenter, Randomized, Open-label, Parallel-group, Diabetic Diet-controlled Study to Evaluate the Efficacy and Safety of Compound α-Keto Acid Tablet in Combination With LPD in Delaying the Progress of Type 2 Diabetic Nephropathy Completed NCT00363987 Phase 4 Ketosteril®
50 Spironolactone in Diabetic Nephropathy Completed NCT00317954 Phase 4 Spironolactone

Search NIH Clinical Center for Microvascular Complications of Diabetes 1

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Becaplermin
benazepril
Benazepril hydrochloride
candesartan
candesartan cilexetil
CAPSACIAN PWDR
Capsaicin
CAPSAICIN PWDR
Capsicum extract
CAPSICUM OLEORESIN
Captopril
Citalopram
Citalopram hydrobromide
COBALAMIN CONCENTRATE
Enalapril
Enalapril Maleate
Enalaprilat
eprosartan
Eprosartan mesylate
Fosinopril
Fosinopril Sodium
Hydroxocobalamin
HYDROXOCOBALAMIN ACETATE
irbesartan
Lisinopril
Losartan
Losartan Potassium
mecobalamin
Mexiletine
Mexiletine Hydrochloride
moexipril
Moexipril hydrochloride
olmesartan
Olmesartan medoxomil
Pentoxifylline
Perindopril
Perindopril arginine
Perindopril Erbumine
quinapril
Quinapril hydrochloride
Ramipril
telmisartan
trandolapril
valsartan
Vitamin B 12

Genetic Tests for Microvascular Complications of Diabetes 1

Genetic tests related to Microvascular Complications of Diabetes 1:

# Genetic test Affiliating Genes
1 Microvascular Complications of Diabetes, Susceptibility to, 1 28 VEGFA

Anatomical Context for Microvascular Complications of Diabetes 1

Organs/tissues related to Microvascular Complications of Diabetes 1:

MalaCards : Retina, Kidney, Eye, Bone Marrow, Endothelial, Spinal Cord, Pancreas

Publications for Microvascular Complications of Diabetes 1

Articles related to Microvascular Complications of Diabetes 1:

(show top 50) (show all 33342)
# Title Authors PMID Year
1
A common polymorphism in the 5'-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. 62 57 5
11978667 2002
2
Vitreous levels of angiopoietin 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy. 53 62 57
15767056 2005
3
SDF-1 is both necessary and sufficient to promote proliferative retinopathy. 53 62 57
15630447 2005
4
Free insulin growth factor-I and vascular endothelial growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy. 53 62 57
12208249 2002
5
Genetic variant in the promoter of connective tissue growth factor gene confers susceptibility to nephropathy in type 1 diabetes. 62 57
20522428 2010
6
Genetic analysis of diabetic nephropathy on chromosome 18 in African Americans: linkage analysis and dense SNP mapping. 62 57
19690890 2009
7
Association of genetic variants at 3q22 with nephropathy in patients with type 1 diabetes mellitus. 62 57
19084216 2009
8
Sequence variants in the PLEKHH2 region are associated with diabetic nephropathy in the GoKinD study population. 62 57
18752002 2008
9
High-density single nucleotide polymorphism genome-wide linkage scan for susceptibility genes for diabetic nephropathy in type 1 diabetes: discordant sibpair approach. 62 57
18559660 2008
10
Association of CC chemokine ligand 5 genotype with urinary albumin excretion in the non-diabetic Japanese general population: the Takahata study. 62 57
18217191 2008
11
Genetic factors in diabetic nephropathy. 62 57
17942768 2007
12
Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation. 62 57
17259996 2007
13
Association of lipoprotein lipase S447X, apolipoprotein E exon 4, and apoC3 -455T>C polymorphisms on the susceptibility to diabetic nephropathy. 62 57
16813599 2006
14
A genome-wide DNA microsatellite association screen to identify chromosomal regions harboring candidate genes in diabetic nephropathy. 62 57
16467450 2006
15
Genetic variations in the gene encoding ELMO1 are associated with susceptibility to diabetic nephropathy. 62 57
15793258 2005
16
Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin superfamily. 62 57
15599399 2004
17
A genome scan for diabetic nephropathy in African Americans. 62 57
15458446 2004
18
RANTES promoter genotype is associated with diabetic nephropathy in type 2 diabetic subjects. 62 57
12610055 2003
19
Reversibility of established diabetic glomerulopathy by anti-TGF-beta antibodies in db/db mice. 62 57
12480514 2003
20
Gene for susceptibility to diabetic nephropathy in type 2 diabetes maps to 18q22.3-23. 62 57
12427143 2002
21
Transforming growth factor beta contributes to progressive diabetic nephropathy. 62 57
10884396 2000
22
Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. 62 57
10859350 2000
23
Deranged transcriptional regulation of cell-volume-sensitive kinase hSGK in diabetic nephropathy. 62 57
10884438 2000
24
Genetics of diabetic nephropathy: evidence for major and minor gene effects. 62 57
10201028 1999
25
Aldose reductase gene expression is increased in diabetic nephropathy. 62 57
9215310 1997
26
Familial factors determine the development of diabetic nephropathy in patients with IDDM. 62 57
8858216 1996
27
Acetylator phenotype in diabetic neuropathy. 62 57
871863 1977
28
Activation of PKC-delta and SHP-1 by hyperglycemia causes vascular cell apoptosis and diabetic retinopathy. 57
19881493 2009
29
Promoter polymorphisms of the pigment epithelium-derived factor gene are associated with diabetic retinopathy. 57
17658465 2007
30
Unbalanced vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor in diabetic retinopathy. 57
12208245 2002
31
Paraoxonase gene cluster is a genetic marker for early microvascular complications in type 1 diabetes. 57
11918623 2002
32
Molecular genetic analysis of the human sorbitol dehydrogenase gene. 57
8535074 1995
33
Dose of intravitreal bevacizumab (Avastin) used as preoperative adjunct therapy for proliferative diabetic retinopathy. 53 62
20453802 2010
34
Roles of endothelin-1 and selected proinflammatory cytokines in the pathogenesis of proliferative diabetic retinopathy: Analysis of vitreous samples. 53 62
20015663 2010
35
Transcription factor, SP1, in epiretinal membranes of patients with proliferative diabetic retinopathy. 53 62
20047772 2010
36
Proliferative diabetic retinopathy and relations among antioxidant activity, oxidative stress, and VEGF in the vitreous body. 53 62
20142849 2010
37
Intravitreous vascular endothelial growth factor and hypoxia-inducible factor 1a in patients with proliferative diabetic retinopathy. 53 62
19837381 2009
38
Extracellular SOD and VEGF are increased in vitreous bodies from proliferative diabetic retinopathy patients. 53 62
20011081 2009
39
Immunohistochemical analysis of cellular adhesion molecules (ICAM-1, VCAM-1) and VEGF in fibrovascular membranes of patients with proliferative diabetic retinopathy: preliminary study. 53 62
18834676 2009
40
Vascular endothelial growth factor-A (VEGF-A) in vitreous fluid of patients with proliferative diabetic retinopathy. 53 62
20214050 2009
41
Vitreous mediators after intravitreal bevacizumab or triamcinolone acetonide in eyes with proliferative diabetic retinopathy. 53 62
19410951 2009
42
Levels of vascular endothelial growth factor and pigment epithelium-derived factor in eyes before and after intravitreal injection of bevacizumab. 53 62
19484443 2009
43
Proliferative diabetic retinopathy-The influence of diabetes control on the activation of the intraocular molecule system. 53 62
19237221 2009
44
[The expression of vascular endothelial growth factor of vitreous in patients with proliferative diabetic retinopathy]. 53 62
19575912 2009
45
Ratio of the vitreous vascular endothelial growth factor and pigment epithelial-derived factor in Eales disease. 53 62
20072643 2009
46
Diabetic retinopathy and angiogenesis. 53 62
19199892 2009
47
Vitreous levels of vasohibin-1 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy. 53 62
19057892 2009
48
Vitreous and serum levels of platelet-derived growth factor and their correlation in patients with proliferative diabetic retinopathy. 53 62
19219687 2009
49
Impact of variants in the VEGF gene on progression of proliferative diabetic retinopathy. 53 62
18709380 2009
50
Novel anti-VEGF chimeric molecules delivered by AAV vectors for inhibition of retinal neovascularization. 53 62
18633446 2009

Variations for Microvascular Complications of Diabetes 1

ClinVar genetic disease variations for Microvascular Complications of Diabetes 1:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 POLR1C, VEGFA NM_003376.6(VEGFA):c.-94C>G SNV Risk Factor
12223 rs2010963 GRCh37: 6:43738350-43738350
GRCh38: 6:43770613-43770613

Expression for Microvascular Complications of Diabetes 1

Search GEO for disease gene expression data for Microvascular Complications of Diabetes 1.

Pathways for Microvascular Complications of Diabetes 1

Pathways related to Microvascular Complications of Diabetes 1 according to GeneCards Suite gene sharing:

(show top 50) (show all 71)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14 VEGFA VCAM1 TIMP1 POLR1C MMP9 ICAM1
2
Show member pathways
13.89 TIMP1 TGFB2 SERPINF1 MMP9 IGF1 HGF
3
Show member pathways
13.83 ANGPT1 ANGPT2 CCL2 CCN2 CXCL12 CXCL8
4 13.8 ANGPT1 CCL2 CXCL12 CXCL8 FGF2 FLT1
5
Show member pathways
13.75 VEGFA TIMP1 TGFB2 MMP9 IGF1 HGF
6
Show member pathways
13.67 VEGFA TIMP1 SERPINF1 MMP9 HGF FLT1
7
Show member pathways
13.59 TIMP1 TGFB2 IGF1 HGF FLT1 FGF2
8
Show member pathways
13.49 VEGFA TIMP1 TGFB2 IGF1 ICAM1 HGF
9
Show member pathways
13.46 VEGFA VCAM1 TGFB2 MMP9 ICAM1 CXCL8
10
Show member pathways
13.4 TIMP1 TGFB2 IGF1 HGF FLT1 FGF2
11
Show member pathways
13.39 VEGFA VCAM1 TIMP1 MMP9 ICAM1 HGF
12
Show member pathways
13.38 TIMP1 TGFB2 IGF1 HGF FLT1 FGF2
13
Show member pathways
13.33 VEGFA TIMP1 TGFB2 IGF1 HGF ANGPT2
14
Show member pathways
13.33 CCN2 CXCL12 FGF2 FLT1 HGF IGF1
15
Show member pathways
13.3 ANGPT1 ANGPT2 CCL2 CCN2 CXCL12 CXCL8
16
Show member pathways
13.13 TIMP1 TGFB2 IGF1 HGF FLT1 FGF2
17
Show member pathways
13.08 CCL2 CCN2 CXCL12 FGF2 FLT1 HGF
18
Show member pathways
13.02 ANGPT1 ANGPT2 FGF2 FLT1 HGF IGF1
19 12.91 VEGFA MMP9 IGF1 HGF GFAP FLT1
20
Show member pathways
12.81 VCAM1 TIMP1 TGFB2 MMP9 ICAM1 FGF2
21
Show member pathways
12.76 TIMP1 TGFB2 IGF1 HGF FLT1 FGF2
22
Show member pathways
12.68 TIMP1 TGFB2 IGF1 HGF FLT1 FGF2
23
Show member pathways
12.65 TIMP1 FGF2 CCL2 ANGPT2 ANGPT1
24 12.55 ANGPT1 ANGPT2 CCL2 CCN2 CXCL12 FGF2
25
Show member pathways
12.53 VEGFA VCAM1 MMP9 ICAM1 CCL2
26
Show member pathways
12.45 TIMP1 TGFB2 IGF1 HGF FLT1 FGF2
27
Show member pathways
12.43 VEGFA VCAM1 ICAM1 CCL2
28 12.32 VEGFA IGF1 HGF FLT1
29 12.16 FGF2 GFAP IGF1 TGFB2
30 12.16 VEGFA VCAM1 IGF1 HGF FGF2
31
Show member pathways
12.13 VEGFA TGFB2 MMP9 IGF1 FGF2
32 12.1 VCAM1 MMP9 ICAM1 CCN2
33 12.08 MMP9 ICAM1 GFAP CXCL8 CCL2
34 11.97 VCAM1 TGFB2 IGF1 FGF2
35 11.97 VEGFA VCAM1 TIMP1 FGF2 CXCL8 CCL2
36 11.92 ANGPT2 CCL2 FGF2 FLT1 HGF MMP9
37 11.89 VEGFA CXCL8 CXCL12
38 11.87 VEGFA IGF1 GFAP FGF2
39 11.85 VEGFA TGFB2 FLT1
40
Show member pathways
11.84 VCAM1 CXCL8 CXCL12
41 11.83 TIMP1 TGFB2 IGF1 HGF FGF2 CXCL12
42 11.81 CCL2 CXCL8 MMP9 TIMP1
43 11.77 FGF2 IGF1 SST
44
Show member pathways
11.76 VEGFA TIMP1 CCL2
45
Show member pathways
11.76 VEGFA VCAM1 MMP9 ICAM1 CXCL8
46 11.75 TIMP1 MMP9 IGF1 CXCL8
47 11.72 TIMP1 MMP9 IGF1 HGF FGF2 CXCL8
48 11.7 VCAM1 ICAM1 CXCL8
49 11.68 VCAM1 ICAM1 CCN2 CCL2
50 11.63 FGF2 HGF IGF1 VEGFA

GO Terms for Microvascular Complications of Diabetes 1

Cellular components related to Microvascular Complications of Diabetes 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.15 ANGPT1 ANGPT2 CCL2 CCN2 CXCL12 CXCL8
2 collagen-containing extracellular matrix GO:0062023 10.06 ANGPT1 ANGPT2 CCN2 CXCL12 ICAM1 MMP9
3 platelet alpha granule lumen GO:0031093 9.96 VEGFA TIMP1 TGFB2 IGF1 HGF
4 extracellular space GO:0005615 9.87 ANGPT1 ANGPT2 CCL2 CCN2 CXCL12 CXCL8

Biological processes related to Microvascular Complications of Diabetes 1 according to GeneCards Suite gene sharing:

(show all 35)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 10.43 VEGFA TIMP1 MMP9 IGF1 HGF ANGPT1
2 positive regulation of gene expression GO:0010628 10.42 ANGPT1 CCN2 CXCL8 FGF2 IGF1 VEGFA
3 positive regulation of cell migration GO:0030335 10.3 VEGFA IGF1 HGF FLT1 CXCL12
4 response to hypoxia GO:0001666 10.24 ANGPT2 CXCL12 TGFB2 VCAM1 VEGFA
5 positive regulation of cell population proliferation GO:0008284 10.24 CCN2 CXCL12 FGF2 FLT1 IGF1 TGFB2
6 aging GO:0007568 10.19 VCAM1 TIMP1 SERPINF1 FGF2 CCN2
7 positive regulation of MAPK cascade GO:0043410 10.18 FGF2 FLT1 HGF IGF1 VEGFA
8 positive regulation of protein phosphorylation GO:0001934 10.18 VEGFA MMP9 HGF FGF2 CCN2 ANGPT1
9 negative regulation of gene expression GO:0010629 10.17 VEGFA TGFB2 SERPINF1 IGF1 FGF2 CXCL8
10 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 10.16 VEGFA IGF1 HGF ANGPT1
11 positive regulation of protein kinase B signaling GO:0051897 10.15 VEGFA IGF1 FGF2 ANGPT1
12 protein kinase B signaling GO:0043491 10.14 IGF1 FGF2 CCL2
13 response to heat GO:0009408 10.14 SST IGF1 CXCL12
14 epithelial to mesenchymal transition GO:0001837 10.13 TGFB2 IGF1 HGF
15 chemotaxis GO:0006935 10.13 CCL2 CXCL12 CXCL8 FGF2 FLT1
16 positive regulation of cell division GO:0051781 10.12 VEGFA TGFB2 FGF2
17 positive regulation of vascular associated smooth muscle cell proliferation GO:1904707 10.11 MMP9 IGF1 FGF2
18 cellular response to amyloid-beta GO:1904646 10.11 VCAM1 IGF1 ICAM1
19 wound healing GO:0042060 10.11 TIMP1 TGFB2 IGF1 FGF2
20 positive regulation of blood vessel endothelial cell migration GO:0043536 10.1 VEGFA FGF2 ANGPT1
21 animal organ regeneration GO:0031100 10.09 HGF CXCL12 ANGPT2
22 cell chemotaxis GO:0060326 10.09 VCAM1 HGF CXCL12 CCL2
23 cellular response to vascular endothelial growth factor stimulus GO:0035924 10.05 FLT1 VCAM1 VEGFA
24 positive chemotaxis GO:0050918 10.03 VEGFA HGF FGF2 ANGPT1
25 positive regulation of angiogenesis GO:0045766 10.03 VEGFA HGF FLT1 FGF2 CXCL8 ANGPT2
26 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.97 ANGPT1 CCL2 CCN2 FGF2 ICAM1 IGF1
27 positive regulation of axon extension involved in axon guidance GO:0048842 9.96 VEGFA CXCL12
28 induction of positive chemotaxis GO:0050930 9.93 VEGFA CXCL8 CXCL12
29 membrane to membrane docking GO:0022614 9.92 ICAM1 VCAM1
30 positive regulation of DNA biosynthetic process GO:2000573 9.91 VEGFA HGF FGF2
31 glomerulus vasculature development GO:0072012 9.89 ANGPT2 ANGPT1
32 Tie signaling pathway GO:0048014 9.88 ANGPT2 ANGPT1
33 angiogenesis GO:0001525 9.83 VEGFA FLT1 FGF2 CXCL8 CCN2 CCL2
34 positive regulation of epithelial tube formation GO:1905278 9.79 VEGFA FGF2
35 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.44 VEGFA TGFB2 IGF1 HGF FLT1 FGF2

Molecular functions related to Microvascular Complications of Diabetes 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 10.03 TGFB2 HGF CXCL12 CCL2 ANGPT2 ANGPT1
2 cytokine activity GO:0005125 9.9 CCL2 CXCL12 CXCL8 FGF2 TGFB2 TIMP1
3 chemokine activity GO:0008009 9.85 CXCL8 CXCL12 CCL2
4 chemoattractant activity GO:0042056 9.8 VEGFA HGF FGF2
5 integrin binding GO:0005178 9.8 VCAM1 IGF1 ICAM1 GFAP FGF2 CXCL12
6 growth factor activity GO:0008083 9.53 VEGFA TIMP1 TGFB2 IGF1 HGF FGF2

Sources for Microvascular Complications of Diabetes 1

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....